Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

Delayed Quote. Delayed  - 07/24 03:24:43 pm
21010 ILa   -1.22%
07/21 TEVA PHARMACEUT : Announces Pricing of Additional CHF1.0 Billion of ..
07/20 TEVA PHARMACEUT : Announces Pricing of Additional €4.0 Billion of Se..
07/19 TEVA PHARMACEUT : Announces Pricing of $15 Billion of Senior Notes i..
News SummaryMost relevantAll newsSector news 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
07/01/2013 | 01:27pm CEST
   By Melodie Warner 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at melodie.warner@dowjones.com

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
share with twitter share with LinkedIn share with facebook
share via e-mail
07/21 TEVA PHARMACEUTICAL : Announces Pricing of Additional CHF1.0 Billion of Senior N..
07/20 TEVA PHARMACEUTICAL : Announces Pricing of Additional €4.0 Billion of Senior Not..
07/19 TEVA PHARMACEUTICAL : Announces Pricing of $15 Billion of Senior Notes in Connec..
07/18DJTEVA PHARMACEUTICAL : Sells $15 Billion of Bonds
07/18DJTEVA PHARMACEUTICAL : Finalizes Bond Sale -- Update
07/18DJTEVA PHARMACEUTICAL : Finalizes Bond Sale
07/18DJTeva Sells $15 Billion of Bonds
07/17 ALLERGAN : Teva Pharmaceutical Industries Ltd. $40B Deal With Allergan Plc , To ..
07/14 TEVA PHARMACEUTICAL : and the Huntington Study Group Announce Publication of Piv..
07/13 Michaels and Hess slide, Teva and JetBlue trade higher
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 Testing Lirilumab In Leukemia And Pridopidine In Huntington's
07/22 Healthcare ratings - upgrades/downgrades
07/22 VIVUS holding its ground against would-be generic makers of Qsymia
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
07/21 Teva prices ?4B debt offering
Financials ($)
Sales 2016 22 838 M
EBIT 2016 7 265 M
Net income 2016 4 717 M
Debt 2016 25 666 M
Yield 2016 2,28%
P/E ratio 2016 12,68
P/E ratio 2017 10,47
EV / Sales 2016 3,33x
EV / Sales 2017 2,84x
Capitalization 50 478 M
More Financials
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 72,1 $
Spread / Average Target 30%
Consensus details
EPS Revisions
More Estimates Revisions
Erez Vigodman President, Chief Executive Officer & Director
Yitzhak Peterburg Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
More Results